Close

Trending

Pfizer vaults into sickle cell market as GBT deal confirmed

ODM standard for CRF design

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Digital health app linked to better outcomes in heart failure

AZ gets FDA nod for Enhertu in first HER2-low cancer

Roche

diggelmann

Diggelmann leaves Roche’s diagnostics division

Piotr Wnuk Roche 0 Comment

Roche has been hit with another exec departure after it said Roland Diggelmann will leave his role as

X

Diggelmann leaves Roche’s diagnostics division

https://pharmaphorum.com/news/diggelmann-leaves-roche/

Market Access/ News/ News/ Novartis/ Roche

Breakthrough designation for Roche/Novartis’ Xolair in food allergies

Piotr Wnuk Genentech, Novartis, Roche, Xolair 0 Comment

Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US

X

Breakthrough designation for Roche/Novartis’ Xolair in food allergies

https://pharmaphorum.com/news/breakthrough-designation-for-roche-novartis-xolair-in-food-allergies/

Iraq Flag 3D Rendering on Blue Sky Building Background

AstraZeneca/ News/ Pfizer/ Roche

Drug firms fight US government’s Iraq corruption probe

Joy Persaud litigation 0 Comment

US Department of Justice investigating J&J, Pfizer, Roche and others

X

Drug firms fight US government’s Iraq corruption probe

https://pharmaphorum.com/news/drug-firms-fight-us-governments-iraq-corruption-probe/

News/ News/ R&D/ Roche/ Top pharmaceutical companies/ UK & Europe

New Huntington’s drug granted priority designation

Joy Persaud European Medicines Agency, Huntington's disease, Roche 0 Comment

Roche’s treatment for Huntington’s disease has received a priority designation by the European regulator, sparking hope that a

X

New Huntington’s drug granted priority designation

https://pharmaphorum.com/news/huntingtons-drug-granted-priority-designation/

News/ News/ R&D/ Roche/ Top stories

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

Joy Persaud multiple sclerosis, Ocrevus, Roche 0 Comment

Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.

X

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

https://pharmaphorum.com/news/roche-ms-ocrevus-blockbuster/

Pfizer backed off, but the price hike game continues

Bristol-Myers Squibb/ Market Access/ News/ News/ News/ Novo Nordisk/ Patients/ Pfizer/ Roche/ Top stories

Pfizer backed off, but the price hike game continues

Piotr Wnuk cancer, Diabetes, Donald Trump, pricing 0 Comment

Donald Trump may have convinced the US pharma giant Pfizer to defer a price increase for dozens of

X

Pfizer backed off, but the price hike game continues

https://pharmaphorum.com/news/pfizer-backed-off-but-the-price-hike-game-continues/

Tecentriq

News/ News/ Oncology/ Roche

Roche to file Tecentriq in triple negative breast cancer

Richard Staines breast cancer, Bristol-Myers Squibb, cancer, Merck & Co, Roche 0 Comment

No other immunotherapies are approved in indication

X

Roche to file Tecentriq in triple negative breast cancer

https://pharmaphorum.com/news/roche-files-tecentriq-triple-negative-breast-cancer/

Roche Rituxan approval

Market Access/ News/ News/ News/ Oncology/ Roche/ Top stories/ UK & Europe

NICE okays Roche rare lung cancer drug after price cut

Richard Staines cancer, lung cancer, Pfizer, Roche 0 Comment

Alecensa has aced Pfizer’s rival in head-to-head trial

X

NICE okays Roche rare lung cancer drug after price cut

https://pharmaphorum.com/market-access-2/nice-okays-roche-rare-lung-cancer-drug-after-price-cut/

NICE1

Market Access/ News/ News/ Roche/ UK & Europe

NICE okays NHS funding for MS and eczema drugs

Richard Staines atopic dermatitis, multiple sclerosis, NICE, Roche, Sanofi 0 Comment

The UK’s NICE endorsed regular NHS funding for big-selling drugs from Roche and Sanofi, changing its mind in

X

NICE okays NHS funding for MS and eczema drugs

https://pharmaphorum.com/news/nice-okays-nhs-funding-for-ms-and-eczema-drugs/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com